Company / SG&A Expense
ADMA Biologics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$91.6M
FY2025
5-year range
$42.9M / $91.6M
FY2021-FY2025
Trend
+23.5%
vs FY2024
Sector context
#119 of 213
Health Care
What the data says
At $92M, ADMA Biologics, Inc.'s sg&a expense ranks #95 of 213 in the Health Care sector. SG&A Expense has increased for 3 consecutive years, from $43M in FY2022 to $92M in FY2025.
Based on SEC 10-K filings.
$92M in FY2025 with a 5-year CAGR of +21.2%.
Increased from $59M to $92M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +28.8%
- 5-Year CAGR
- +21.2%
- 10-Year CAGR
- -
Sector benchmark
#95 of 213 in Health CareTop 44% of 213This company $91.6M Sector average $722.3M
▼
-87.3% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +21.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 23.5% year-over-year.
- Ranks #119 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $91.6M | +23.5% |
| FY2024 | $74.1M | +25.6% |
| FY2023 | $59.0M | +37.6% |
| FY2022 | $42.9M | -0.0% |
| FY2021 | $42.9M | +22.4% |
| FY2020 | $35.1M | +35.3% |
| FY2019 | $25.9M | +15.1% |
| FY2018 | $22.5M | +164.9% |
| FY2017 | $8.5M | +0.0% |
| FY2016 | $8.5M | +76.1% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026